Some studies report an ongoing decline in AMH several years after cancer treatment in adult females.[25] For this reason it is important to measure AMH despite normal menstrual cycles in young female survivors of OS or other diagnoses, as they may have a diminished ovarian follicular reserve despite having FSH and LH levels within the normal range. The gene discussed is BRD2; the disease is cancer.